Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection
infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory im...
Saved in:
Published in | Frontiers in immunology Vol. 11; p. 1011 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
09.06.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the main antibody class found in mucous secretions, including human milk, and serves as the first line of defense for the gastrointestinal epithelium against enteric pathogens. In this study, we describe the prophylactic activity of orally delivered recombinant SIgA generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility and highly conserved across
species associated with severe enteritis. In an immunocompetent weaned mouse model, a single oral administration of FliD-reactive SIgA CAA1 or CCG4 at 2 h before infection significantly enhances
clearance at early stages post-infection, reducing the levels of inflammation markers associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a comparable protective effect. Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of
infections as well as the development of post-infection syndromes. |
---|---|
AbstractList | Campylobacter
infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the main antibody class found in mucous secretions, including human milk, and serves as the first line of defense for the gastrointestinal epithelium against enteric pathogens. In this study, we describe the prophylactic activity of orally delivered recombinant SIgA generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility and highly conserved across
Campylobacter
species associated with severe enteritis. In an immunocompetent weaned mouse model, a single oral administration of FliD-reactive SIgA CAA1 or CCG4 at 2 h before infection significantly enhances
Campylobacter
clearance at early stages post-infection, reducing the levels of inflammation markers associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a comparable protective effect. Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of
Campylobacter
infections as well as the development of post-infection syndromes. Campylobacter infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the main antibody class found in mucous secretions, including human milk, and serves as the first line of defense for the gastrointestinal epithelium against enteric pathogens. In this study, we describe the prophylactic activity of orally delivered recombinant SIgA generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility and highly conserved across Campylobacter species associated with severe enteritis. In an immunocompetent weaned mouse model, a single oral administration of FliD-reactive SIgA CAA1 or CCG4 at 2 h before infection significantly enhances Campylobacter clearance at early stages post-infection, reducing the levels of inflammation markers associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a comparable protective effect. Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of Campylobacter infections as well as the development of post-infection syndromes. Campylobacter infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the main antibody class found in mucous secretions, including human milk, and serves as the first line of defense for the gastrointestinal epithelium against enteric pathogens. In this study, we describe the prophylactic activity of orally delivered recombinant SIgA generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility and highly conserved across Campylobacter species associated with severe enteritis. In an immunocompetent weaned mouse model, a single oral administration of FliD-reactive SIgA CAA1 or CCG4 at 2 h before infection significantly enhances Campylobacter clearance at early stages post-infection, reducing the levels of inflammation markers associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a comparable protective effect. Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of Campylobacter infections as well as the development of post-infection syndromes.Campylobacter infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the main antibody class found in mucous secretions, including human milk, and serves as the first line of defense for the gastrointestinal epithelium against enteric pathogens. In this study, we describe the prophylactic activity of orally delivered recombinant SIgA generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility and highly conserved across Campylobacter species associated with severe enteritis. In an immunocompetent weaned mouse model, a single oral administration of FliD-reactive SIgA CAA1 or CCG4 at 2 h before infection significantly enhances Campylobacter clearance at early stages post-infection, reducing the levels of inflammation markers associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a comparable protective effect. Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of Campylobacter infections as well as the development of post-infection syndromes. infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the main antibody class found in mucous secretions, including human milk, and serves as the first line of defense for the gastrointestinal epithelium against enteric pathogens. In this study, we describe the prophylactic activity of orally delivered recombinant SIgA generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility and highly conserved across species associated with severe enteritis. In an immunocompetent weaned mouse model, a single oral administration of FliD-reactive SIgA CAA1 or CCG4 at 2 h before infection significantly enhances clearance at early stages post-infection, reducing the levels of inflammation markers associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a comparable protective effect. Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of infections as well as the development of post-infection syndromes. |
Author | Piantanida, Renato Grassi, Fabio Morone, Diego Jaconi, Stefano Perruzza, Lisa Pinna, Debora Hu, Yue Joshi, Sangeeta Bagai Seehusen, Frauke Xiong, Jian Kumru, Ozan Selahattin Benigni, Fabio Corti, Davide Pizzuto, Matteo Samuele Strati, Francesco Bajoria, Sakshi Lombardo, Gloria Volkin, David Bernard |
AuthorAffiliation | 3 Laboratory for Animal Model Pathology (LAMP), Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich , Zurich , Switzerland 4 Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas , Lawrence, KS , United States 5 Department of Otolaryngology–Head and Neck Surgery, Ospedale Regionale di Lugano , Lugano , Switzerland 1 Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI) , Bellinzona , Switzerland 2 Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc. , Bellinzona , Switzerland |
AuthorAffiliation_xml | – name: 3 Laboratory for Animal Model Pathology (LAMP), Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich , Zurich , Switzerland – name: 4 Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas , Lawrence, KS , United States – name: 1 Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI) , Bellinzona , Switzerland – name: 2 Humabs BioMed SA a Subsidiary of Vir Biotechnology Inc. , Bellinzona , Switzerland – name: 5 Department of Otolaryngology–Head and Neck Surgery, Ospedale Regionale di Lugano , Lugano , Switzerland |
Author_xml | – sequence: 1 givenname: Lisa surname: Perruzza fullname: Perruzza, Lisa – sequence: 2 givenname: Stefano surname: Jaconi fullname: Jaconi, Stefano – sequence: 3 givenname: Gloria surname: Lombardo fullname: Lombardo, Gloria – sequence: 4 givenname: Debora surname: Pinna fullname: Pinna, Debora – sequence: 5 givenname: Francesco surname: Strati fullname: Strati, Francesco – sequence: 6 givenname: Diego surname: Morone fullname: Morone, Diego – sequence: 7 givenname: Frauke surname: Seehusen fullname: Seehusen, Frauke – sequence: 8 givenname: Yue surname: Hu fullname: Hu, Yue – sequence: 9 givenname: Sakshi surname: Bajoria fullname: Bajoria, Sakshi – sequence: 10 givenname: Jian surname: Xiong fullname: Xiong, Jian – sequence: 11 givenname: Ozan Selahattin surname: Kumru fullname: Kumru, Ozan Selahattin – sequence: 12 givenname: Sangeeta Bagai surname: Joshi fullname: Joshi, Sangeeta Bagai – sequence: 13 givenname: David Bernard surname: Volkin fullname: Volkin, David Bernard – sequence: 14 givenname: Renato surname: Piantanida fullname: Piantanida, Renato – sequence: 15 givenname: Fabio surname: Benigni fullname: Benigni, Fabio – sequence: 16 givenname: Fabio surname: Grassi fullname: Grassi, Fabio – sequence: 17 givenname: Davide surname: Corti fullname: Corti, Davide – sequence: 18 givenname: Matteo Samuele surname: Pizzuto fullname: Pizzuto, Matteo Samuele |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32582158$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1v1DAQhiNUREvpnRPykUsWf8e5IEVbCisVFfFxthxnsvXKsRcnu1L-Pd7dUrVI-GBb9jPveDzv6-IsxABF8ZbgBWOq_tC7YdgtKKZ4gQkm5EVxQaTkJaOUnz3ZnxdX47jBefCaMSZeFeeMCkWJUBfF5luK2_vZGzs5i5o87900o9iju2S8n1HTDS64cYIEHbrx7rr8Dgd4D-hrDNH6GIxHP1brBjVr48I4oaUZtrOPbcYgoVXoIfMxvCle9saPcPWwXha_bj79XH4pb-8-r5bNbWm5pFMpcCeZULWsAERtWCWg7SwFLBiulWxJRSnNxQgQPRctw0YJYqWsVFuD5IxdFquTbhfNRm-TG0yadTROHw9iWmuTcrUeNOOUcCZqhlvMJTFKciUr1vWY1QxMn7U-nrS2u3aAzkKY8rc8E31-E9y9Xse9rmgtcUWywPsHgRR_72Cc9OBGC96bAHE3aspJxTGpFM3ou6e5HpP8bVYG8AmwKY5jgv4RIVgfLKGPltAHS-ijJXKI_CfEuskcupFf6_z_A_8A1X67Iw |
CitedBy_id | crossref_primary_10_1080_21645515_2021_1964317 crossref_primary_10_3390_ijms25105487 crossref_primary_10_1016_j_chom_2022_04_007 crossref_primary_10_1016_j_xphs_2023_04_005 crossref_primary_10_1021_acsinfecdis_0c00842 |
Cites_doi | 10.1111/j.1651-2227.1993.tb12574.x 10.1371/journal.pone.0008805 10.1099/00221287-131-8-1973 10.1371/journal.ppat.1004264 10.1556/EuJMI.2.2012.1.2 10.1086/644622 10.1371/journal.pbio.1001658 10.1146/annurev.mi.37.100183.003131 10.1155/2013/526860 10.1038/mi.2011.41 10.1073/pnas.0402391101 10.1002/eji.201444816 10.4049/jimmunol.114.1_Part_2.284 10.1016/S2214-109X(15)00151-5 10.1016/j.vaccine.2016.02.080 10.7554/eLife.10640 10.1038/nrgastro.2011.191 10.1007/978-0-387-72232-0 10.1038/nature22058 10.1038/nature13764 10.1016/S0378-1097(01)00332-9 10.1128/AAC.32.8.1107 10.1002/eji.200839129 10.1128/IAI.01094-05 10.7554/eLife.18857 10.1111/j.1651-2227.1989.tb11225.x 10.1016/S1074-7613(02)00341-2 10.1038/nri1393 10.1212/WNL.51.2.371 10.1053/j.gastro.2009.04.001 10.1016/j.vaccine.2016.02.052 10.3389/fcimb.2014.00077 10.1128/IAI.00833-06 10.1016/j.xphs.2019.07.018 10.1074/jbc.M104529200 10.1038/35001088 10.1073/pnas.77.12.7257 10.1016/S0022-3476(05)82652-6 10.1111/cmi.12714 10.1371/journal.pone.0043976 10.1016/j.ebiom.2016.07.030 10.1111/j.0105-2896.2005.00278.x 10.1128/CMR.00006-15 10.1371/journal.pone.0015060 10.1016/j.celrep.2018.03.027 10.1371/journal.ppat.1007083 10.1099/jmm.0.060095-0 10.1371/journal.pone.0020953 10.1038/nm1080 10.1016/j.jmb.2017.02.001 |
ContentType | Journal Article |
Copyright | Copyright © 2020 Perruzza, Jaconi, Lombardo, Pinna, Strati, Morone, Seehusen, Hu, Bajoria, Xiong, Kumru, Joshi, Volkin, Piantanida, Benigni, Grassi, Corti and Pizzuto. Copyright © 2020 Perruzza, Jaconi, Lombardo, Pinna, Strati, Morone, Seehusen, Hu, Bajoria, Xiong, Kumru, Joshi, Volkin, Piantanida, Benigni, Grassi, Corti and Pizzuto. 2020 Perruzza, Jaconi, Lombardo, Pinna, Strati, Morone, Seehusen, Hu, Bajoria, Xiong, Kumru, Joshi, Volkin, Piantanida, Benigni, Grassi, Corti and Pizzuto |
Copyright_xml | – notice: Copyright © 2020 Perruzza, Jaconi, Lombardo, Pinna, Strati, Morone, Seehusen, Hu, Bajoria, Xiong, Kumru, Joshi, Volkin, Piantanida, Benigni, Grassi, Corti and Pizzuto. – notice: Copyright © 2020 Perruzza, Jaconi, Lombardo, Pinna, Strati, Morone, Seehusen, Hu, Bajoria, Xiong, Kumru, Joshi, Volkin, Piantanida, Benigni, Grassi, Corti and Pizzuto. 2020 Perruzza, Jaconi, Lombardo, Pinna, Strati, Morone, Seehusen, Hu, Bajoria, Xiong, Kumru, Joshi, Volkin, Piantanida, Benigni, Grassi, Corti and Pizzuto |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.3389/fimmu.2020.01011 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_3421435930b0461a8648673df0393eaf PMC7296071 32582158 10_3389_fimmu_2020_01011 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Bill and Melinda Gates Foundation |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c462t-50d6358967ee59a375ebdc2e0530986b172220005e5f45b30a851c6678b9e6433 |
IEDL.DBID | M48 |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:16:13 EDT 2025 Thu Aug 21 13:40:02 EDT 2025 Fri Jul 11 02:55:00 EDT 2025 Mon Jul 21 05:55:54 EDT 2025 Tue Jul 01 00:40:05 EDT 2025 Thu Apr 24 23:04:26 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | FliD flagellar-capping protein prophylaxis secretory IgA Campylobacter monoclonal antibodies |
Language | English |
License | Copyright © 2020 Perruzza, Jaconi, Lombardo, Pinna, Strati, Morone, Seehusen, Hu, Bajoria, Xiong, Kumru, Joshi, Volkin, Piantanida, Benigni, Grassi, Corti and Pizzuto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c462t-50d6358967ee59a375ebdc2e0530986b172220005e5f45b30a851c6678b9e6433 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology Edited by: Juraj Ivanyi, King's College London, United Kingdom Reviewed by: Armando Acosta, Universiti Sains Malaysia Health Campus, Malaysia; Jiri Mestecky, University of Alabama at Birmingham, United States |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2020.01011 |
PMID | 32582158 |
PQID | 2417401782 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3421435930b0461a8648673df0393eaf pubmedcentral_primary_oai_pubmedcentral_nih_gov_7296071 proquest_miscellaneous_2417401782 pubmed_primary_32582158 crossref_primary_10_3389_fimmu_2020_01011 crossref_citationtrail_10_3389_fimmu_2020_01011 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-06-09 |
PublicationDateYYYYMMDD | 2020-06-09 |
PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-09 day: 09 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2020 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Watanabe (B13) 2016; 10 Corti (B38) 2010; 5 Song (B25) 2017; 429 Pappas (B27) 2014; 516 Taylor (B42) 1988; 32 Traggiai (B28) 2004; 10 Man (B4) 2011; 8 Rochereau (B20) 2013; 11 Riddle (B2) 2016; 34 Giallourou (B48) 2018; 14 Bereswill (B39) 2011; 6 Moor (B19) 2017; 544 Hu (B30) 2019; 109 Stahl (B31) 2014; 10 Masanta (B40) 2013; 2013 B1 B5 Maurer (B44) 2018; 23 Haag (B43) 2012; 2 Glass (B24) 1989; 351 Kaetzel (B17) 2005; 206 Kaakoush (B3) 2015; 28 Postel (B32) 2016; 5 Rochereau (B37) 2015; 45 Platts-Mills (B6) 2015; 3 Heimesaat (B46) 2014; 4 Phalipon (B18) 2002; 17 Plaut (B36) 1983; 37 de Oliveira (B45) 2001; 203 Torres (B23) 1993; 82 Ruiz-Palacios (B22) 1990; 116 Lindh (B49) 1975; 114 Tribble (B51) 2009; 49 Islam (B7) 2012; 7 Gradel (B9) 2009; 137 Mantis (B14) 2011; 4 Freitag (B33) 2017; 19 Stadtmueller (B15) 2016; 5 Pinna (B35) 2009; 39 Yeh (B34) 2014; 63 Chang (B41) 2006; 74 Thibault (B11) 2001; 276 Kaetzel (B29) 2007 Zhang (B50) 2010; 5 Mansfield (B47) 2007; 75 Labbok (B21) 2004; 4 Chintoan-Uta (B26) 2016; 34 Yuki (B8) 2004; 101 Parkhill (B12) 2000; 403 Sheikh (B52) 1998; 51 Mostov (B16) 1980; 77 Morooka (B10) 1985; 131 |
References_xml | – volume: 82 start-page: 835 year: 1993 ident: B23 article-title: Protection against Campylobacter diarrhea: role of milk IgA antibodies against bacterial surface antigens publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.1993.tb12574.x – volume: 5 start-page: e8805 year: 2010 ident: B38 article-title: Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals publication-title: PLoS ONE doi: 10.1371/journal.pone.0008805 – volume: 131 start-page: 1973 year: 1985 ident: B10 article-title: Motility as an intestinal colonization factor for Campylobacter jejuni publication-title: J Gen Microbiol doi: 10.1099/00221287-131-8-1973 – volume: 10 start-page: e1004264 year: 2014 ident: B31 article-title: A novel mouse model of Campylobacter jejuni gastroenteritis reveals key pro-inflammatory and tissue protective roles for Toll-like receptor signaling during infection publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1004264 – volume: 2 start-page: 2 year: 2012 ident: B43 article-title: Campylobacter jejuni infection of infant mice: acute enterocolitis is followed by asymptomatic intestinal and extra-intestinal immune responses publication-title: Eur J Microbiol Immunol doi: 10.1556/EuJMI.2.2012.1.2 – volume: 49 start-page: 1512 year: 2009 ident: B51 article-title: Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects publication-title: Clin Infect Dis doi: 10.1086/644622 – volume: 11 start-page: e1001658 year: 2013 ident: B20 article-title: Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells publication-title: PLoS Biol doi: 10.1371/journal.pbio.1001658 – volume: 37 start-page: 603 year: 1983 ident: B36 article-title: The IgA1 proteases of pathogenic bacteria publication-title: Annu Rev Microbiol doi: 10.1146/annurev.mi.37.100183.003131 – volume: 2013 start-page: 526860 year: 2013 ident: B40 article-title: Modification of intestinal microbiota and its consequences for innate immune response in the pathogenesis of campylobacteriosis publication-title: Clin Dev Immunol doi: 10.1155/2013/526860 – volume: 4 start-page: 603 year: 2011 ident: B14 article-title: Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut publication-title: Mucosal Immunol doi: 10.1038/mi.2011.41 – volume: 101 start-page: 11404 year: 2004 ident: B8 article-title: Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes guillain-Barre syndrome publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0402391101 – volume: 45 start-page: 773 year: 2015 ident: B37 article-title: Secretory IgA as a vaccine carrier for delivery of HIV antigen to M cells publication-title: Eur J Immunol doi: 10.1002/eji.201444816 – volume: 114 start-page: 284 year: 1975 ident: B49 article-title: Increased risistance of immunoglobulin A dimers to proteolytic degradation after binding of secretory component publication-title: J Immunol doi: 10.4049/jimmunol.114.1_Part_2.284 – volume: 3 start-page: e564 year: 2015 ident: B6 article-title: Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED) publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(15)00151-5 – volume: 34 start-page: 2903 year: 2016 ident: B2 article-title: Status of vaccine research and development for Campylobacter jejuni publication-title: Vaccine doi: 10.1016/j.vaccine.2016.02.080 – volume: 5 start-page: e10640 year: 2016 ident: B15 article-title: The structure and dynamics of secretory component and its interactions with polymeric immunoglobulins publication-title: Elife doi: 10.7554/eLife.10640 – volume: 8 start-page: 669 year: 2011 ident: B4 article-title: The clinical importance of emerging campylobacter species publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2011.191 – start-page: 2 volume-title: Mucosal Immune Defense: Immunoglobulin A year: 2007 ident: B29 article-title: The structure of IgA doi: 10.1007/978-0-387-72232-0 – volume: 544 start-page: 498 year: 2017 ident: B19 article-title: High-avidity IgA protects the intestine by enchaining growing bacteria publication-title: Nature doi: 10.1038/nature22058 – volume: 516 start-page: 418 year: 2014 ident: B27 article-title: Rapid development of broadly influenza neutralizing antibodies through redundant mutations publication-title: Nature doi: 10.1038/nature13764 – volume: 203 start-page: 29 year: 2001 ident: B45 article-title: Binding of lactoferrin and free secretory component to enterotoxigenic Escherichia coli publication-title: FEMS Microbiol Lett doi: 10.1016/S0378-1097(01)00332-9 – volume: 32 start-page: 1107 year: 1988 ident: B42 article-title: Mechanisms of antibiotic resistance in Campylobacter species publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.32.8.1107 – volume: 39 start-page: 1260 year: 2009 ident: B35 article-title: Clonal dissection of the human memory B-cell repertoire following infection and vaccination publication-title: Eur J Immunol doi: 10.1002/eji.200839129 – volume: 74 start-page: 5261 year: 2006 ident: B41 article-title: Campylobacter jejuni colonization of mice with limited enteric flora publication-title: Infect Immun doi: 10.1128/IAI.01094-05 – volume: 5 start-page: e18857 year: 2016 ident: B32 article-title: Bacterial flagellar capping proteins adopt diverse oligomeric states publication-title: Elife doi: 10.7554/eLife.18857 – volume: 351 start-page: 131 year: 1989 ident: B24 article-title: The protective effect of human milk against diarrhea. A review of studies from Bangladesh publication-title: Acta Paediatr Scand Suppl doi: 10.1111/j.1651-2227.1989.tb11225.x – volume: 17 start-page: 107 year: 2002 ident: B18 article-title: Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo publication-title: Immunity doi: 10.1016/S1074-7613(02)00341-2 – volume: 4 start-page: 565 year: 2004 ident: B21 article-title: Breastfeeding: maintaining an irreplaceable immunological resource publication-title: Nat Rev Immunol doi: 10.1038/nri1393 – volume: 51 start-page: 371 year: 1998 ident: B52 article-title: Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility publication-title: Neurology doi: 10.1212/WNL.51.2.371 – volume: 137 start-page: 495 year: 2009 ident: B9 article-title: Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.04.001 – volume: 34 start-page: 1739 year: 2016 ident: B26 article-title: Evaluation of flagellum-related proteins FliD and FspA as subunit vaccines against Campylobacter jejuni colonisation in chickens publication-title: Vaccine doi: 10.1016/j.vaccine.2016.02.052 – ident: B1 – volume: 4 start-page: 77 year: 2014 ident: B46 article-title: The role of serine protease HtrA in acute ulcerative enterocolitis and extra-intestinal immune responses during Campylobacter jejuni infection of gnotobiotic IL-10 deficient mice publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2014.00077 – ident: B5 – volume: 75 start-page: 1099 year: 2007 ident: B47 article-title: C57BL/6 and congenic interleukin-10-deficient mice can serve as models of Campylobacter jejuni colonization and enteritis publication-title: Infect Immun doi: 10.1128/IAI.00833-06 – volume: 109 start-page: 407 year: 2019 ident: B30 article-title: Preformulation characterization and stability assessments of secretory IgA monoclonal antibodies as potential candidates for passive immunization by oral administration publication-title: J Pharm Sci. doi: 10.1016/j.xphs.2019.07.018 – volume: 276 start-page: 34862 year: 2001 ident: B11 article-title: Identification of the carbohydrate moieties and glycosylation motifs in Campylobacter jejuni flagellin publication-title: J Biol Chem doi: 10.1074/jbc.M104529200 – volume: 403 start-page: 665 year: 2000 ident: B12 article-title: The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences publication-title: Nature doi: 10.1038/35001088 – volume: 77 start-page: 7257 year: 1980 ident: B16 article-title: Receptor-mediated transcellular transport of immunoglobulin: synthesis of secretory component as multiple and larger transmembrane forms publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.77.12.7257 – volume: 116 start-page: 707 year: 1990 ident: B22 article-title: Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milk publication-title: J Pediatr doi: 10.1016/S0022-3476(05)82652-6 – volume: 19 start-page: 1 year: 2017 ident: B33 article-title: Host cell binding of the flagellar tip protein of Campylobacter jejuni publication-title: Cell Microbiol doi: 10.1111/cmi.12714 – volume: 7 start-page: e43976 year: 2012 ident: B7 article-title: Guillain-Barre syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies publication-title: PLoS ONE doi: 10.1371/journal.pone.0043976 – volume: 10 start-page: 25 year: 2016 ident: B13 article-title: Environmental enteropathy: elusive but significant subclinical abnormalities in developing countries publication-title: EBioMedicine. doi: 10.1016/j.ebiom.2016.07.030 – volume: 206 start-page: 83 year: 2005 ident: B17 article-title: The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2005.00278.x – volume: 28 start-page: 687 year: 2015 ident: B3 article-title: Global epidemiology of campylobacter infection publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00006-15 – volume: 5 start-page: e15060 year: 2010 ident: B50 article-title: Genomic characterization of the Guillain-Barre syndrome-associated Campylobacter jejuni ICDCCJ07001 isolate publication-title: PLoS ONE doi: 10.1371/journal.pone.0015060 – volume: 23 start-page: 90 year: 2018 ident: B44 article-title: Glycosylation of human IgA directly inhibits influenza A and other sialic-acid-binding viruses publication-title: Cell Rep doi: 10.1016/j.celrep.2018.03.027 – volume: 14 start-page: e1007083 year: 2018 ident: B48 article-title: A novel mouse model of Campylobacter jejuni enteropathy and diarrhea publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1007083 – volume: 63 start-page: 602 year: 2014 ident: B34 article-title: Characterization and antigenicity of recombinant Campylobacter jejuni flagellar capping protein FliD publication-title: J Med Microbiol doi: 10.1099/jmm.0.060095-0 – volume: 6 start-page: e20953 year: 2011 ident: B39 article-title: Novel murine infection models provide deep insights into the “menage a trois” of Campylobacter jejuni, microbiota and host innate immunity publication-title: PLoS ONE doi: 10.1371/journal.pone.0020953 – volume: 10 start-page: 871 year: 2004 ident: B28 article-title: An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus publication-title: Nat Med doi: 10.1038/nm1080 – volume: 429 start-page: 847 year: 2017 ident: B25 article-title: Self-oligomerizing structure of the flagellar cap protein FliD and its implication in filament assembly publication-title: J Mol Biol doi: 10.1016/j.jmb.2017.02.001 |
SSID | ssj0000493335 |
Score | 2.2815056 |
Snippet | infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic... Campylobacter infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development... Campylobacter infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1011 |
SubjectTerms | Animals Antibodies, Bacterial - metabolism Antibodies, Monoclonal - metabolism Bacterial Proteins - immunology Bacterial Vaccines - immunology Campylobacter Campylobacter - physiology Campylobacter Infections - immunology Disease Models, Animal Disease Resistance Female flagellar-capping protein FliD Gastroenteritis - immunology Humans Immunoglobulin A - metabolism Immunology Immunotherapy - methods Intestinal Mucosa - immunology Mice Mice, Inbred C57BL monoclonal antibodies Neutrophils - immunology prophylaxis secretory IgA |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NTxsxELUQUqVeUFsKXWiRK3HhsMRZr_fjmAIRqQRUhUjcLNuxIdGyi2hyyL_vjL2JEoTgwnU_rZmx543seY-QQ6a5dSNt47xwLk51xuLCOh4rxboK6pVMc2xOvrjMzofp71txuyL1hWfCAj1wMFyHpwmm9JIzjdzgqsiQI46PHDaVWuVw9YWct1JMTQLu5ZyLsC8JVVjZceOHhxnUgwk7Rlq17loe8nT9L2HM50clV3JP_xPZakEj7YXBfiYbtv5CPgQZyfk2mfx5asBale93oj0TBCFo4-gVfKya0wVDLupy0n41Po3_WuUXOgpzujEVwnF6Pbjr0d6dGgNipLgnMUeyECRzpoP2yFb9lQz7Zzcn53GroRCbNEumsWAjgBRFmeXWilLxXFg9MgkKQrCyyDTglwS7dYQVLhWaMwUQzGSQwnRpAa3wHbJZN7X9RigYXKS5M6ZrYHlVUKjZlCkNgC3VlidlRDoLi0rTEoyjzkUlodBAH0jvA4k-kN4HETlavvEYyDVeefYXOmn5HNJi-wsQLLINFvlWsETk58LFEqYR7o2o2jazfxKADGoTAl6KyG5w-fJXPMFuYlFEJF8LhrWxrN-px_eeqhtKFyTw23uPwe-Tj2gOf06t_E42p08z-wMQ0VQf-OD_DzscB28 priority: 102 providerName: Directory of Open Access Journals |
Title | Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32582158 https://www.proquest.com/docview/2417401782 https://pubmed.ncbi.nlm.nih.gov/PMC7296071 https://doaj.org/article/3421435930b0461a8648673df0393eaf |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFL1CQ6C9IMbXAmwyEi88ZHPjOB8PCHVA2ZAGCKjUN8t27dIpS6BrJfrvd6-TlhUVXvrQJmnqe517Tu17DsBLboTzY-PivPA-Tk3G48J5EWvNexr5SmYENSeff8pOh-nHkRz9aY_uBvBqK7UjP6nhrDr6_Wv5Bif8a2KcWG-P_fTycoFUL-FHpJiGXOg21qWc_AzOO7B_0WJhIYRs1yq3nrgLd0VCnaNkAH-jTAU1_20Q9O-dlDdK0-A-3OswJeu3SbAHt1z9AO60LpPLh3DxZdbgYFahHYr1besXwRrPPuPFqiVbCeiSbScbVNN38Venw3OQ4ZRvbEVonX07m_RZf6KnCCgZLVksSUuEtJ7ZWbejq34Ew8H7729P485iIbZplsxjyceIOIoyy52TpRa5dGZsE_KL4GWRGRzFhJp5pJM-lUZwjQjNZljhTOkQzIjHsFM3tdsHxkUp09xb27P49NXI41zKtUE8lxonkjKC49WIKtvpj5MNRqWQh1A4VAiHonCoEI4IXq3P-Nlqb_zn2BMK0vo4Us0ObzSzieomoRJpQvCwFNyQzrwuMtIbFGNPDcpO-wherEKscJbR0omuXbO4UpRPyEQRTkXwpA35-qtWKRNBvpEMG_ey-Uk9_RGUvJHZkL7f039e8xns0m8Me9PK57Azny3cAaKguTkM_x7g64dR7zAk-jWyewYU |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prophylactic+Activity+of+Orally+Administered+FliD-Reactive+Monoclonal+SIgA+Against+Campylobacter+Infection&rft.jtitle=Frontiers+in+immunology&rft.au=Perruzza%2C+Lisa&rft.au=Jaconi%2C+Stefano&rft.au=Lombardo%2C+Gloria&rft.au=Pinna%2C+Debora&rft.date=2020-06-09&rft.eissn=1664-3224&rft.volume=11&rft.spage=1011&rft_id=info:doi/10.3389%2Ffimmu.2020.01011&rft_id=info%3Apmid%2F32582158&rft.externalDocID=32582158 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |